Lenalidomide (revlimid, CC-5013) in myelodysplastic syndromes: Is it any good?

Current Hematologic Malignancy Reports

Volumn 1, Issue 1, 2006, Pages 16-19

  Sekeres, Mikkael A ^b   List, Alan ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

LENALIDOMIDE; THALIDOMIDE;

BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CHROMOSOME 5Q; CHROMOSOME DELETION; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; HUMAN; MYELODYSPLASTIC SYNDROME; NEUROLOGIC DISEASE; NEUTROPENIA; PERIPHERAL NEUROPATHY; PROGNOSIS; PRURITUS; QUALITY OF LIFE; REVIEW; THROMBOCYTOPENIA; URTICARIA;

BLOOD TRANSFUSION; CLINICAL TRIALS, PHASE I AS TOPIC; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; IMMUNOLOGIC FACTORS; MULTICENTER STUDIES AS TOPIC; MYELODYSPLASTIC SYNDROMES; SURVIVAL ANALYSIS; THALIDOMIDE; TREATMENT OUTCOME;

EID: 33750367323     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-006-0012-9     Document Type: Review

References (21)

1. Bennett JM, Catovsky D, Daniel MT, et al.: Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982, 51:189-199.
2. Harris NL, Jaffe ES, Diebold J, et al.: The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 1999, 10:1419-1432.
3. Greenberg P, Cox C, LeBeau MM, et al.: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088. The most widely accepted prognostic system in the myelodysplastic syndromes, based on an analysis of 816 patients.
4. Boultwood J, Lewis S, Wainscoat JS: The 5q- syndrome. Blood 1994, 84:3253-3260.
5. Allampallam K, Shetty V, Mundle S, et al.: Biological significance of proliferation, apoptosis, cytokines, and monocyte/macrophage cells in bone marrow biopsies of 145 patients with myelodysplastic syndrome. Int J Hematol 2002, 75:289-297.
6. Bellamy WT, Richter L, Sirjani D, et al.: Vascular endothelial cell growth factor is an autocrine promoter of abnormal localized immature myeloid precursors and leukemia progenitor formation in myelodysplastic syndromes. Blood 2001, 97:1427-1434.
7. Kitajima S, Kudo Y, Ogawa I, Bashir T: Overexpression of tumor necrosis factor (TNF)-α and interferon (IFN)-γ by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 1997, 12:2049-2054.
8. Cheson BD, Bennett JM, Kantarjian H, et al.: Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000, 96:3671-3674. The standard for clinical trial response criteria in MDS.
9. Cheson BD, Bennett JM, Kantarjian H, et al.: Myelodysplastic syndromes standardized response criteria: further definition. Blood 2001, 98:1985.
10. Hellstrom-Lindberg E, Schmidt-Mende J, Forsblom AM, et al.: Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 1997, 99:344-351.
11. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, et al.: A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003, 120:1037-1046. A useful algorithm to predict which patients will respond to growth factor stimulation.
12. Corral LG, Kaplan G: Immunomodulation by thalidomide and thalidomide analogues. Ann Rheum Dis 1999, 58(Suppl 1):I107-I113.
13. Davies FE, Raje N, Hideshima T, et al.: Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 2001, 98:210-216.
14. Geitz H, Handt S, Zwingenberger K: Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade. Immunopharmacology 1996, 31:213-221.
15. Parman T, Wiley MJ, Wells PG: Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity. Nat Med 1999, 5:582-585.
16. Raza A, Meyer P, Dutt D, et al.: Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001, 98:958-965. The largest study of single agent thalidomide as a treatment of MDS.
17. Musto P, Falcone A, Sanpaolo G, et al.: Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes. Haematologica 2002, 87:884-886.
18. Strupp C, Germing U, Scherer A, et al.: Thalidomide for the treatment of patients with myelodysplastic syndromes. Leukemia 2002, 16:1-6.
19. Moreno-Aspitia A, Geyer S, Li C-Y, et al.: Multicenter phase II trial of thalidomide (thal) in adult patients with myelodysplastic syndromes (MDS) [abstract]. Blood 2002, 100:Abstract N998B.
20. List A, Tate W, Glinsmann-Gibson B: The immunomodulatory thalidomide analog, CC-5013, inhibits trophic response in VEGF in AML cells by abolishing cytokine-induced PI3 kinase/Akt activation [abstract]. Blood 2002, 100:139.
21. List A, Kurtin S, Roe DJ, et al.: Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005, 352:11-19. The study that demonstrates the remarkable efficacy of lenalidomide in early MDS, and particularly in patients with deletion of 5q31.1.